Inflammation and the development of pancreatic cancer

Surgical Oncology

Volumn 10, Issue 4, 2002, Pages 153-169

  Farrow, Buckminster ^a   Evers, B Mark ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Anti inflammatory drugs; DNA damage; Pancreatic cancer; Pancreatitis; Reactive oxygen species

Indexed keywords

2 [1 CARBOXY 2 [4 [2 (5 METHYL 2 PHENYL 4 OXAZOLYL)ETHOXY]PHENYL]ETHYLAMINO]BENZOIC ACID METHYL ESTER; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ADVANCED GLYCATION END PRODUCT; ANTIOXIDANT; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CANCER VACCINE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; GAMMA INTERFERON; GELATINASE A; GELATINASE B; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; NITRIC OXIDE SYNTHASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLATELET DERIVED GROWTH FACTOR; PROTEIN P53; REACTIVE OXYGEN METABOLITE; SMAD PROTEIN; STAT3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TROGLITAZONE; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

BACTERIAL INFECTION; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CARCINOGENESIS; CELL CYCLE; CELL PROLIFERATION; CHRONIC PANCREATITIS; CLINICAL TRIAL; CYTOKINE RELEASE; DISEASE COURSE; DNA DAMAGE; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION; GENE MUTATION; HEPATITIS; HUMAN; LIVER CELL CARCINOMA; LIVER TOXICITY; MICROSATELLITE INSTABILITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ONCOGENE; PANCREAS CANCER; PANCREAS CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTOZOAL INFECTION; REVIEW; RISK FACTOR; STOMACH CANCER;

CARCINOMA; CYCLOOXYGENASE 2; CYTOKINES; DNA DAMAGE; HUMANS; INFLAMMATION; INTERLEUKIN-1; ISOENZYMES; MEMBRANE PROTEINS; NF-KAPPA B; OXIDATIVE STRESS; PANCREATIC NEOPLASMS; PANCREATITIS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036093865     PISSN: 09607404     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-7404(02)00015-4     Document Type: Review

References (170)

1. Cancer statistics, 2001
2. Recent cancer trends in the United States
3. Pancreaticoduodenectomy for pancreatic adenocarcinoma: Postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience
4. Preoperative staging and assessment of resectability of pancreatic cancer
5. Pancreatic cancer: State-of-the-art care
6. Inflammation and cancer: Back to Virchow?
7. Burn scar carcinoma. Diagnosis and management
8. Inflammatory bowel disease and colon cancer: A review
9. Increased risk of large-bowel cancer in Crohn's disease with colonic involvement
10. Colon cancer in ulcerative colitis
11. Dysplasia and cancer in ulcerative colitis
12. Landscaping the cancer terrain
13. Increased risk of cancer in the Peutz-Jeghers syndrome
14. Very high risk of cancer in familial Peutz-Jeghers syndrome
15. Pancreatic adenocarcinoma in a patient with Peutz-Jeghers syndrome: Report of a case and literature review
16. The decline in gastric cancer: Epidemiology of an unplanned triumph
17. Helicobacter pylori infection and the risk of gastric carcinoma
18. Association of Helicobacter pylori infection with gastric carcinoma: A meta-analysis
19. Infection with Helicobacter pylori strains possessing cagA is associated with an increased risk of developing adenocarcinoma of the stomach
20. How does Helicobacter pylori cause mucosal damage? Its effect on acid and gastrin physiology
21. Helicobacter pylori stimulates antral mucosal reactive oxygen metabolite production in vivo
22. Production of reactive oxygen species by gastric cells in association with Helicobacter pylori
23. Genetic errors, cell proliferation, and carcinogenesis
24. Cell proliferation in carcinogenesis
25. Increased oxidative DNA damage in Helicobacter pylori-infected human gastric mucosa
26. Helicobacter pylori eradication and antral intestinal metaplasia - 2yr follow-up study
27. Effect of Helicobacter pylori eradication on gastric histology, serum gastrin and pepsinogen I levels, and gastric emptying in patients with gastric ulcer
28. Long-term follow-up of gastric histology after Helicobacter pylori eradication
29. Effect of Helicobacter pylori eradication on gastritis in relation to cagA: A prospective 1-year follow-up study
30. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22,707 men in Taiwan
31. The long-term serological course of asymptomatic hepatitis B virus carriers and the development of primary hepatocellular carcinoma
32. Expression of hepatitis B virus large envelope polypeptide inhibits hepatitis B surface antigen secretion in transgenic mice
33. Molecular pathogenesis of hepatocellular carcinoma in hepatitis B virus transgenic mice
34. Extensive oxidative DNA damage in hepatocytes of transgenic mice with chronic active hepatitis destined to develop hepatocellular carcinoma
35. A lack of direct role of hepatitis B virus in the activation of ras and c-myc oncogenes in human hepatocellular carcinogenesis
36. Prognostic factors for hepatocellular carcinoma in genetic hemochromatosis
37. Hepatocellular carcinoma in primary biliary cirrhosis: Similar incidence to that in hepatitis C virus-related cirrhosis
38. Human hepatitis C virus NS5A protein alters intracellular calcium levels, induces oxidative stress, and activates STAT-3 and NF-kappa B
39. Series introduction: The transcription factor NF-kappaB and human disease
40. Mitogenic and antiapoptotic actions of hepatocyte growth factor through ERK, Stat3, and Akt in endothelial cells
41. NF-kappaB as a primary regulator of the stress response
42. Infection with liver flukes (Opisthorchis viverrini, Opisthorchis felineus and Clonorchis sinensis)
43. Chronic infections and inflammatory processes as cancer risk factors: Possible role of nitric oxide in carcinogenesis
44. Bacterial and parasitic cholangitis
45. Human pathology of Opisthorchis viverrini infection: A comparison of adults and children
46. Cancer of the bladder and infestation with Schistosoma haematobium
47. The incidence of squamous and transitional cell carcinomas of the urinary bladder in northern Tanzania in areas of high and low levels of endemic Schistosoma haematobium infection
48. Inflammation, chromosomal instability, and cancer: The schistosomiasis model
49. Involvement of inflammatory reactions and elevated cell proliferation in the development of bladder cancer in schistosomiasis patients
50. Micronucleus frequencies in urothelial cells of catheterized patients with chronic bladder inflammation
51. Hashimoto thyroiditis associated with thyroid cancer in adolescent patients
52. Carcinoma in chronic thyroiditis
53. Incidence of cancer in struma lympomatosa
54. Antibodies that promote thyroid growth. A distinct population of thyroid-stimulating autoantibodies
55. Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group
56. Hereditary pancreatitis and pancreatic carcinoma
57. Pancreatic cancer surveillance in a high-risk cohort. Is it worth the cost?
58. Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group
59. Tumor-suppressive pathways in pancreatic carcinoma
60. K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization
61. Overexpression of p53 protein in adenocarcinoma of the pancreas
62. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1
63. Analysis of K-ras oncogene mutations in chronic pancreatitis with ductal hyperplasia
64. Genetic progression in the pancreatic ducts
65. Acute pancreatitis
66. Chronic pancreatitis
67. The role of cytokines in the pathogenesis of acute pancreatitis
68. Growth factors and cytokines in pancreatic carcinogenesis
69. Molecular regulation of constitutive expression of interleukin-8 in human pancreatic adenocarcinoma
70. Classification of pancreatitis
71. Chronic pancreatitis: Clinical features and medical management
72. Tumor necrosis factor (TNF) up-regulates the expression of p75 but not p55 TNF receptors, and both receptors mediate, independently of each other, up-regulation of transforming growth factor alpha and epidermal growth factor receptor mRNA
73. Macrophages infiltrating the tissue in chronic pancreatitis express the chemokine receptor CCR5
74. The role of the macrophage in wound repair. A study with hydrocortisone and antimacrophage serum
75. Induction of neovascularization in vivo and endothelial proliferation in vitro by tumor-associated macrophages
76. Detection and localization of Mip-3alpha/LARC/Exodus, a macrophage proinflammatory chemokine, and its CCR6 receptor in human pancreatic cancer
77. Tumors and fibrinogen. The role of fibrinogen as an extracellular matrix protein
78. Invasion-specific genes in malignancy: Serial analysis of gene expression comparisons of primary and passaged cancers
79. Tumor progression: Defining the soil round the tumor seed
80. Tumors: Wounds that do not heal. Similarities between tumor stroma generation and wound healing
81. Tumor necrosis factor alpha and interleukin 11 secreted by malignant breast epithelial cells inhibit adipocyte differentiation by selectively down-regulating CCAAT/enhancer binding protein alpha and peroxisome proliferator-activated receptor gamma: Mechanism of desmoplastic reaction
82. Peroxisome proliferator-activated receptors: Insight into multiple cellular functions
83. Salicylates inhibit NF-kappaB activation and enhance TNF-alpha-induced apoptosis in human pancreatic cancer cells
84. Promoter of the human NF-kappa B p50/p105 gene. Regulation by NF-kappa B subunits and by c-REL
85. The NF-kappa B and I kappa B proteins: New discoveries and insights
86. Aberrant rel/nfkb genes and activity in human cancer
87. NF-kappaB: A key role in inflammatory diseases
88. Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer
89. Increased cyclin D1 in human pancreatic cancer is associated with decreased postoperative survival
90. The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells
91. Abnormal glucose metabolism and pancreatic cancer mortality
92. Leukocyte-endothelial interaction is augmented by high glucose concentrations and hyperglycemia in a NF-kB-dependent fashion
93. Glucose and diabetic vascular disease
94. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins
95. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta
96. Cooperation between transcription factor AP-1 and NF-kappaB in the induction of interleukin-8 in human pancreatic adenocarcinoma cells by hypoxia
97. Autocrine growth effect of IL-8 and GROalpha on a human pancreatic cancer cell line, Capan-1
98. Constitutive and inducible interleukin 8 expression by hypoxia and acidosis renders human pancreatic cancer cells more tumorigenic and metastatic
99. Cyclooxygenase is an immediate-early gene induced by interleukin-1 in human endothelial cells
100. The role of COX-2 in intestinal cancer
101. Increased expression of cyclooxygenase-2 in human pancreatic neoplasms and potential for chemoprevention by cyclooxygenase inhibitors
102. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer
103. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells
104. Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice
105. Islet cells as a component of pancreatic ductal neoplasms. I. Experimental study: Ductular cells, including islet cell precursors, as primary progenitor cells of tumors
106. Stimulation of islet cell proliferation enhances pancreatic ductal carcinogenesis in the hamster model
107. Sugar pills for pancreatic cancer: The benefits of becoming (insulin) sensitive
108. Overexpression of cyclooxygenase-2 in carcinoma of the pancreas
109. The nuclear receptor PPARgamma - Bigger than fat
110. Unraveling the mechanism of action of thiazolidinediones
111. 15-Deoxy-Delta(12,14)-prostaglandin J(2) induces G(1) arrest and differentiation marker expression in vascular smooth muscle cells
112. Induction of differentiation and apoptosis by ligands of peroxisome proliferator-activated receptor gamma in non-small cell lung cancer
113. PPAR-gamma is selectively upregulated in Caco-2 cells by butyrate
114. Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma
115. Activation of peroxisome proliferator-activated receptor gamma by troglitazone inhibits cell growth through the increase of p27KiP1 in human. Pancreatic carcinoma cells
116. PPARgamma ligand (thiazolidinedione) induces growth arrest and differentiation markers of human pancreatic cancer cells
117. Chronic immune activation and inflammation as the cause of malignancy
118. The contribution of endogenous sources of DNA damage to the multiple mutations in cancer
119. Helicobacter pylori eradication attenuates oxidative stress in human gastric mucosa
120. Diet, Helicobacter pylori, and p53 mutations in gastric cancer: A molecular epidemiology study in Italy
121. Inducible nitric oxide synthase, nitrotyrosine, and apoptosis in Helicobacter pylori gastritis: Effect of antibiotics and antioxidants
122. Nitric oxide-mediated inhibition of DNA repair potentiates oxidative DNA damage in cholangiocytes
123. Alcohol and smoking as risk factors in chronic pancreatitis and pancreatic cancer
124. Long-term tobacco smoking and colorectal cancer in a prospective cohort study
125. A cohort study of stomach cancer in a high-risk American population
126. Cigarette smoking and cancer of the pancreas: Evidence from a population-based case-control study in Toronto, Canada
127. Inflammation and cancer: Role of phagocyte-generated oxidants in carcinogenesis
128. Histologic changes in pancreas in relation to smoking and coffee-drinking habits
129. Cigarette smoking as a risk factor for pancreatic cancer in patients with hereditary pancreatitis
130. The risk of pancreatic cancer following pancreatitis: An association due to confounding?
131. Role of oxidative DNA damage in cancer initiation and promotion
132. Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis: A cancer-prone chronic inflammatory disease
133. Expression of inducible nitric oxide synthase and nitrotyrosine in colonic epithelium in inflammatory bowel disease
134. Damage to DNA by reactive oxygen and nitrogen species: Role in inflammatory disease and progression to cancer
135. Microsatellite instability in nonneoplastic mucosa from patients with chronic ulcerative colitis
136. Lipid peroxidation and glutathione metabolism in chronic pancreatitis
137. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis
138. Oxidative stress in acute and chronic pancreatitis
139. Genomic instability is an early event during the progression pathway of ulcerative-colitis-related neoplasia
140. Genetic instability and the mutator phenotype. Studies in ulcerative colitis
141. Pancolonic chromosomal instability precedes dysplasia and cancer in ulcerative colitis
142. Comparative analysis of histology, DNA content, p53 and Ki-ras mutations in colectomy specimens with long-standing ulcerative colitis
143. Microsatellite instability: Marker of a mutator phenotype in cancer
144. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer
145. Microsatellite instability and K-ras mutations associated with pancreatic adenocarcinoma and pancreatitis
146. Macrophage migration inhibitory factor induces phagocytosis of foreign particles by macrophages in autocrine and paracrine fashion
147. A proinflammatory cytokine inhibits p53 tumor suppressor activity
148. Toward a new generation of vaccines: The anti-cytokine therapeutic vaccines
149. Clinical trials of antibody therapy
150. Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials
151. Impaired tumorigenicity of human pancreatic cancer cells retrovirally transduced with interleukin-12 or interleukin-15 gene
152. Immunoregulation in pancreatic cancer patients
153. Rel/NF-kappa B and I kappa B factors in oncogenesis
154. Biological and biochemical inhibitors of the NF-kappa B/Rel proteins and cytokine synthesis
155. The role of NF-kappaB/IkappaB proteins in cancer: Implications for novel treatment strategies
156. Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: Down-regulation of COX-2 and iNOS through suppression of NF-kappa B activation
157. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors
158. Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo
159. Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer
160. Drg-1 as a differentiation-related, putative metastatic suppressor gene in human colon cancer
161. Tumor suppressor and anti-inflammatory actions of PPARgamma agonists are mediated via upregulation of PTEN
162. A new ligand for the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), GW7845, inhibits rat mammary carcinogenesis
163. Oxy-radicals and cancer
164. Modulation of pancreatic carcinogenesis by antioxidants
165. Cancer risk and oxidative DNA damage in man
166. The p53-deficient mouse: A model for basic and applied cancer studies
167. Selected features of nonendocrine pancreatic cancer